{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:17:42Z","timestamp":1790201862563,"version":"4.1.0"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"the National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2020R1F1A1069257"],"award-info":[{"award-number":["NRF-2020R1F1A1069257"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"crossref","award":["K2413951"],"award-info":[{"award-number":["K2413951"]}],"id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The comparative effectiveness of individual sodium\u2013glucose cotransporter-2 inhibitors (SGLT-2is) in preventing ischemic cardiovascular disease (CVD) remains uncertain. Thus, this study compared the incidence of ischemic CVD events in patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin or empagliflozin in combination with metformin. This retrospective cohort study analyzed national claims data from the Korean National Health Insurance Service. Patients with T2DM who received dapagliflozin or empagliflozin, combined with metformin, between 2014 and 2019 were included. The primary outcome was composite ischemic CVD events, defined as myocardial infarction, ischemic stroke, or coronary revascularization. Secondary outcomes included each component of composite ischemic CVD events, unstable angina, and all-cause mortality. Hazard ratios (HRs) and confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusting for covariates in three stepwise models: Model 1 (age and sex), Model 2 (Model 1 variables plus patient characteristics), and Model 3 (Model 2 variables plus clinical parameters). In Model 3, after full adjustment for systolic blood pressure, low-density lipoprotein cholesterol, fasting blood glucose, and serum creatinine, no significant difference was observed in the incidence of composite ischemic CVD events between dapagliflozin and empagliflozin when each was used in combination with metformin (adjusted HR 0.50, 95% CI: 0.24\u20131.03). Additionally, no significant differences were observed in individual components of composite ischemic CVD events, unstable angina, and all-cause mortality. These real-world findings may help in selecting an SGLT-2is subtype for CVD prevention in Asian patients with T2DM.<\/jats:p>","DOI":"10.1371\/journal.pone.0333604","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T17:28:49Z","timestamp":1760635729000},"page":"e0333604","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study"],"prefix":"10.1371","volume":"20","author":[{"given":"Hayeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjoo","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-696X","authenticated-orcid":true,"given":"Kyungim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"pone.0333604.ref001","doi-asserted-by":"crossref","first-page":"1192629","DOI":"10.3389\/fendo.2023.1192629","article-title":"The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019","volume":"14","author":"J Ye","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"pone.0333604.ref002","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-8587(23)00223-1","article-title":"Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation","volume":"11","author":"Emerging Risk Factors Collaboration","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"pone.0333604.ref003","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.jacc.2021.02.030","article-title":"Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial","volume":"77","author":"I Cavallari","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9733","key":"pone.0333604.ref004","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"key":"pone.0333604.ref005","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1464-5491.2010.03075.x","article-title":"A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland","volume":"27","author":"KN Barnett","year":"2010","journal-title":"Diabet Med"},{"issue":"3","key":"pone.0333604.ref006","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/diacare.26.3.848","article-title":"Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience","volume":"26","author":"Intervention Trial Research group","year":"2003","journal-title":"Diabetes Care"},{"key":"pone.0333604.ref007","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","article-title":"Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison","volume":"79","author":"MD Kelsey","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"pone.0333604.ref008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis","volume":"6","author":"DK McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"3","key":"pone.0333604.ref009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"M Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"23","key":"pone.0333604.ref010","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study","volume":"71","author":"M Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"pone.0333604.ref011","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0333604.ref012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"SD Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0333604.ref013","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10741-020-09954-8","article-title":"Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"26","author":"T T\u00e4ger","year":"2021","journal-title":"Heart Fail Rev"},{"key":"pone.0333604.ref014","doi-asserted-by":"crossref","first-page":"802992","DOI":"10.3389\/fendo.2022.802992","article-title":"Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Y Jiang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0333604.ref015","article-title":"Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials","volume":"100","author":"XY Duan","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"pone.0333604.ref016","article-title":"The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis","volume":"16","author":"T Sinha","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"pone.0333604.ref017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus","volume":"21","author":"Y Suzuki","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"pone.0333604.ref018","article-title":"Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease","volume":"17","author":"J Lim","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0333604.ref019","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-023-01911-7","article-title":"Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study","volume":"22","author":"J Lim","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"pone.0333604.ref020","article-title":"Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus","volume":"47","author":"J-H Kim","year":"2024","journal-title":"Clin Cardiol"},{"issue":"1","key":"pone.0333604.ref021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","article-title":"Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study","volume":"18","author":"S-C Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0333604.ref022","article-title":"Identification and Predictors for Cardiovascular Disease Risk Equivalents among Adults With Diabetes Mellitus","author":"Y Zhao","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"pone.0333604.ref023","doi-asserted-by":"crossref","first-page":"167","DOI":"10.24171\/j.phrp.2018.9.4.05","article-title":"Factors that Correlate with Poor Glycemic Control in Type 2 Diabetes Mellitus Patients with Complications","volume":"9","author":"M Haghighatpanah","year":"2018","journal-title":"Osong Public Health Res Perspect"},{"issue":"5","key":"pone.0333604.ref024","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies","volume":"40","author":"L Azoulay","year":"2017","journal-title":"Diabetes Care"},{"key":"pone.0333604.ref025","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials","volume":"18","author":"FB Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"pone.0333604.ref026","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcad.2017.09.001","article-title":"Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes","volume":"60","author":"ME Herman","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"pone.0333604.ref027","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ehf2.12345","article-title":"Empagliflozin, calcium, and SGLT1\/2 receptor affinity: another piece of the puzzle","volume":"5","author":"SD Anker","year":"2018","journal-title":"ESC Heart Fail"},{"key":"pone.0333604.ref028","first-page":"133","article-title":"Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes","volume":"11","author":"I Papakitsou","year":"2019","journal-title":"Clin Pharmacol"},{"issue":"2","key":"pone.0333604.ref029","article-title":"Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis","volume":"15","author":"L Xu","year":"2025","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0333604.ref030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"6","author":"DS Shyangdan","year":"2016","journal-title":"BMJ Open"},{"issue":"22","key":"pone.0333604.ref031","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/CIRCULATIONAHA.121.056756","article-title":"Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study","volume":"145","author":"RB Goldberg","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"pone.0333604.ref032","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"SJ Griffin","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"pone.0333604.ref033","first-page":"799","article-title":"Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"S Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"4","key":"pone.0333604.ref034","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"E von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"pone.0333604.ref035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4093\/dmj.2022.0375","article-title":"Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey","volume":"47","author":"JH Baek","year":"2023","journal-title":"Diabetes Metab J"},{"issue":"1","key":"pone.0333604.ref036","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","article-title":"Identifying diabetes cases from administrative data: a population-based validation study","volume":"18","author":"LL Lipscombe","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"pone.0333604.ref037","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/dom.16086","article-title":"Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial","volume":"27","author":"R Usui","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"pone.0333604.ref038","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"E Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"pone.0333604.ref039","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.2337\/dc12-2691","article-title":"Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study","volume":"36","author":"AA van der Heijden","year":"2013","journal-title":"Diabetes Care"},{"key":"pone.0333604.ref040","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.lanepe.2023.100651","article-title":"Risk of recurrent stroke in Rotterdam between 1990 and 2020: a population-based cohort study","volume":"30","author":"BP Berghout","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"pone.0333604.ref041","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13300-017-0320-1","article-title":"SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review","volume":"8","author":"A Rastogi","year":"2017","journal-title":"Diabetes Ther"},{"issue":"4","key":"pone.0333604.ref042","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"S Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"11","key":"pone.0333604.ref043","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care"},{"issue":"9","key":"pone.0333604.ref044","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/dme.13384","article-title":"Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data","volume":"34","author":"KH Ha","year":"2017","journal-title":"Diabet Med"},{"issue":"7","key":"pone.0333604.ref045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","article-title":"Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study","volume":"8","author":"S Kohsaka","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"pone.0333604.ref046","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.122.20489","article-title":"Systolic Blood Pressure and Cardiovascular Risk in Patients With Diabetes: A Prospective Cohort Study","volume":"80","author":"S Rao","year":"2023","journal-title":"Hypertension"},{"issue":"9","key":"pone.0333604.ref047","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1161\/STROKEAHA.113.001624","article-title":"Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals","volume":"44","author":"SAE Peters","year":"2013","journal-title":"Stroke"},{"issue":"32","key":"pone.0333604.ref048","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"BA Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"pone.0333604.ref049","first-page":"754","article-title":"The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications","volume":"70","author":"R Elosua","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"17","key":"pone.0333604.ref050","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.101.17.2047","article-title":"Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality","volume":"101","author":"M Wei","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"pone.0333604.ref051","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.2337\/dc12-1577","article-title":"Fasting glucose level and the risk of incident atherosclerotic cardiovascular diseases","volume":"36","author":"C Park","year":"2013","journal-title":"Diabetes Care"},{"issue":"25","key":"pone.0333604.ref052","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/CIRCULATIONAHA.108.792903","article-title":"Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study","volume":"118","author":"T Ninomiya","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"pone.0333604.ref053","article-title":"Different cardiovascular risks associated with elevated creatinine-based eGFR and cystatin C-based eGFR","volume":"1","author":"M Liu","year":"2024","journal-title":"npj Cardiovasc Health"},{"key":"pone.0333604.ref054","doi-asserted-by":"crossref","first-page":"1140093","DOI":"10.3389\/fendo.2023.1140093","article-title":"Serum creatinine levels, traditional cardiovascular risk factors and 10-year cardiovascular risk in Chinese patients with hypertension","volume":"14","author":"X Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0333604.ref055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","article-title":"Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study","volume":"151","author":"EJ Ku","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"pone.0333604.ref056","article-title":"Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes","volume":"13","author":"M Hussain","year":"2021","journal-title":"Cureus"},{"issue":"11","key":"pone.0333604.ref057","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.jdiacomp.2020.107704","article-title":"Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis","volume":"34","author":"M Fralick","year":"2020","journal-title":"J Diabetes Complications"},{"issue":"2","key":"pone.0333604.ref058","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review","volume":"20","author":"K Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pone.0333604.ref059","doi-asserted-by":"crossref","first-page":"1301093","DOI":"10.3389\/fendo.2023.1301093","article-title":"Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review","volume":"14","author":"X Xie","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"pone.0333604.ref060","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/dme.12232","article-title":"Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis","volume":"30","author":"OJ Phung","year":"2013","journal-title":"Diabet Med"},{"key":"pone.0333604.ref061","doi-asserted-by":"crossref","first-page":"2040622319880392","DOI":"10.1177\/2040622319880392","article-title":"Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction","volume":"10","author":"R Peters","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"pone.0333604.ref062","volume-title":"National health screening statistical yearbook","author":"National Health Insurance Service NHIS","year":"2015"},{"issue":"3","key":"pone.0333604.ref063","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4082\/kjfm.22.0052","article-title":"Current Status of the National Health Screening Programs in South Korea","volume":"43","author":"H-T Kang","year":"2022","journal-title":"Korean J Fam Med"},{"issue":"23","key":"pone.0333604.ref064","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2024.06.050","article-title":"2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study","volume":"84","author":"C Gyldenkerne","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"pone.0333604.ref065","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.jacc.2023.08.015","article-title":"10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus","volume":"82","author":"C Gyldenkerne","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"pone.0333604.ref066","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.120.046783","article-title":"Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings","volume":"142","author":"AK Wright","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"pone.0333604.ref067","article-title":"Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus","volume":"19","author":"DK Song","year":"2024","journal-title":"PLoS One"},{"issue":"6","key":"pone.0333604.ref068","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4093\/dmj.2024.0275","article-title":"Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019","volume":"48","author":"Diabetic Vascular Disease Research Group of the Korean Diabetes Association","year":"2024","journal-title":"Diabetes Metab J"},{"issue":"3","key":"pone.0333604.ref069","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00125-018-4796-7","article-title":"Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015","volume":"62","author":"SH Read","year":"2019","journal-title":"Diabetologia"},{"issue":"3","key":"pone.0333604.ref070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.36011\/cpp.2025.7.e13","article-title":"2024 Cardio-cerebrovascular disease fact sheet in Korea","volume":"7","author":"K Han","year":"2025","journal-title":"CPP"},{"issue":"12","key":"pone.0333604.ref071","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00125-006-0493-z","article-title":"Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database","volume":"49","author":"HE Mulnier","year":"2006","journal-title":"Diabetologia"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T17:29:01Z","timestamp":1760635741000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333604"}},"subtitle":[],"editor":[{"given":"Marwan Salih","family":"Al-Nimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":71,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0333604","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}